Central effects in man of the novel schistosomicidal benzodiazepine meclonazepam - PubMed (original) (raw)

Clinical Trial

Central effects in man of the novel schistosomicidal benzodiazepine meclonazepam

C O'Boyle et al. Eur J Clin Pharmacol. 1985.

Abstract

The novel benzodiazepine derivative, meclonazepam (3-methylclonazepam) has been found to be orally effective at high doses against all stages of schistosomiasis. Animals studies have shown it to have a high therapeutic index and a profile of behavioural activity typical of the benzodiazepines. The effects of single oral doses of meclonazepam, 1, 2 and 4 mg on central arousal, psychomotor performance and subjective mood were studied in two double-blind placebo controlled studies in healthy volunteers. In doses exceeding 1 mg, meclonazepam caused marked dose-related impairment in cognitive and psychomotor functions as well as shifts in mood reflecting sedation and ataxia. These effects were most prominent in the first 3 h after administration, with moderate sedation still present 6 h after the 4 mg dose. The implications of these findings for the use of benzodiazepine agents in the treatment of schistosomiasis are discussed.

PubMed Disclaimer

References

    1. Br J Clin Pharmacol. 1982 Nov;14(5):677-82 - PubMed
    1. Psychopharmacologia. 1973 Sep 28;32(3):223-35 - PubMed
    1. Br J Anaesth. 1981 Nov;53(11):1179-88 - PubMed
    1. Nature. 1981 Apr 9;290(5806):514-6 - PubMed
    1. Naunyn Schmiedebergs Arch Pharmacol. 1978 Oct;304(3):309-15 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources